Last reviewed · How we verify

NCT05929313

Scoreflex TRIO - Scoring PTCA Catheter

Completed NA Last updated 26 August 2024
What this trial tests

NA trial testing OrbusNeich Scoreflex TRIO in Coronary Arteriosclerosis in 210 participants. Completed in 29 May 2024.

Timeline
27 April 2023
Primary endpoint
30 April 2024
29 May 2024

Quick facts

Lead sponsorOrbusNeich
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment210
Start date27 April 2023
Primary completion30 April 2024
Estimated completion29 May 2024
Sites4 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

OrbusNeich — full company profile →

Who can join

Adults 18 to 80, any sex, with Coronary Arteriosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the acute safety and device procedural success of the Scoreflex TRIO Scoring PTCA catheters versus Scoreflex NC Scoring PTCA catheters in subjects with stenotic coronary arteries during percutaneous coronary intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Coronary Arteriosclerosis

Currently open trials in the same condition.

Other OrbusNeich trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05929313.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing